Literature DB >> 27025710

Population-Based Epidemiology and Mortality of Small Malignant Gastrointestinal Stromal Tumors in the USA.

Taylor M Coe1, Katherine E Fero1, Paul T Fanta1,2, Robert J Mallory3, Chih-Min Tang3, James D Murphy1,4, Jason K Sicklick5,6.   

Abstract

BACKGROUND AND AIMS: Gastrointestinal stromal tumors (GISTs) have significant variability in size and malignant behavior. Our current understanding is limited to pathological analyses, autopsy studies, and small case series. The aim of the current study is to define the risk factors, incidence, and mortality rates of GIST <2 cm in the National Cancer Institute's Surveillance, Epidemiology, and End Results database.
METHODS: Patients with histologically confirmed malignant GIST <2 cm were studied from 2001 to 2011. GIST was defined by GI tumor site codes and GIST-specific histology codes.
RESULTS: We identified 378 patients with GIST <2 cm. The average age at diagnosis was 64.0 years with equal sex distribution. The most common tumor location was the stomach (62.2 %), followed by the small intestine (23.3 %), colon (5.6 %), and rectum (3.4 %). Most patients had localized disease (79.4 %), but 11.4 % had regional/distant metastatic disease. The annual incidence rate was 4.2 per 10,000,000 (10M). This was the highest among Blacks (7.6 per 10M). Among patients with GIST and no additional cancers, the 5-year GIST-specific mortality was 12.9 %. Moreover, there was a significantly increased 5-year GIST-specific mortality in those patients who had regionally advanced (34.0 %) or metastatic GIST (34.3 %), as compared to those patients with localized GIST (5.6 %).
CONCLUSIONS: This study represents the first population-based analysis of malignant GIST <2 cm. While quite rare, these tumors have an underappreciated disease-specific mortality. Further studies are needed to define the underlying reasons for the identified racial differences, to develop novel risk assessment schema for patients with these small tumors, and to determine appropriate indications for resection and/or medical therapy.

Entities:  

Keywords:  GIST tumorlet; ICC hyperplasia; Minute GIST; Small GIST

Mesh:

Year:  2016        PMID: 27025710      PMCID: PMC4880518          DOI: 10.1007/s11605-016-3134-y

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  25 in total

1.  Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

Authors:  R P DeMatteo; J J Lewis; D Leung; S S Mudan; J M Woodruff; M F Brennan
Journal:  Ann Surg       Date:  2000-01       Impact factor: 12.969

2.  Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up.

Authors:  Markku Miettinen; Leslie H Sobin; Jerzy Lasota
Journal:  Am J Surg Pathol       Date:  2005-01       Impact factor: 6.394

3.  Increased risk of additional cancers among patients with gastrointestinal stromal tumors: A population-based study.

Authors:  James D Murphy; Grace L Ma; Joel M Baumgartner; Lisa Madlensky; Adam M Burgoyne; Chih-Min Tang; Maria Elena Martinez; Jason K Sicklick
Journal:  Cancer       Date:  2015-04-30       Impact factor: 6.860

4.  Underreporting of Gastrointestinal Stromal Tumors: Is the True Incidence Being Captured?

Authors:  Audrey H Choi; John B Hamner; Shaila J Merchant; Vijay Trisal; Warren Chow; Carlos A Garberoglio; Joseph Kim
Journal:  J Gastrointest Surg       Date:  2015-05-22       Impact factor: 3.452

5.  Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations.

Authors:  Abbas Agaimy; Peter H Wünsch; Ferdinand Hofstaedter; Hagen Blaszyk; Petra Rümmele; Andreas Gaumann; Wolfgang Dietmaier; Arndt Hartmann
Journal:  Am J Surg Pathol       Date:  2007-01       Impact factor: 6.394

6.  High incidence of microscopic gastrointestinal stromal tumors in the stomach.

Authors:  Kaori Kawanowa; Yuji Sakuma; Shinji Sakurai; Tsunekazu Hishima; Yoshiaki Iwasaki; Kana Saito; Yoshinori Hosoya; Takashi Nakajima; Nobuaki Funata
Journal:  Hum Pathol       Date:  2006-09-25       Impact factor: 3.466

7.  Epidemiology of gastrointestinal stromal tumors in the era of histology codes: results of a population-based study.

Authors:  Grace L Ma; James D Murphy; Maria E Martinez; Jason K Sicklick
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-10-02       Impact factor: 4.254

Review 8.  Gastrointestinal stromal tumors.

Authors:  Markku Miettinen; Jerzy Lasota
Journal:  Gastroenterol Clin North Am       Date:  2013-03-13       Impact factor: 3.806

9.  Survival of gastrointestinal stromal tumor patients in the imatinib era: life raft group observational registry.

Authors:  Jerry Call; Christopher D Walentas; Jens C Eickhoff; Norman Scherzer
Journal:  BMC Cancer       Date:  2012-03-19       Impact factor: 4.430

10.  Impact of age and gender on tumor related prognosis in gastrointestinal stromal tumors (GIST).

Authors:  Klaus Kramer; Uwe Knippschild; Benjamin Mayer; Kira Bögelspacher; Hanno Spatz; Doris Henne-Bruns; Abbas Agaimy; Matthias Schwab; Michael Schmieder
Journal:  BMC Cancer       Date:  2015-02-14       Impact factor: 4.430

View more
  14 in total

Review 1.  Incidental Gastrointestinal Stromal Tumors (GISTs) and Bariatric Surgery: A Review.

Authors:  J A Fernández; M D Frutos; J J Ruiz-Manzanera
Journal:  Obes Surg       Date:  2020-07-24       Impact factor: 4.129

Review 2.  Racial Disparity in Gastrointestinal Cancer Risk.

Authors:  Hassan Ashktorab; Sonia S Kupfer; Hassan Brim; John M Carethers
Journal:  Gastroenterology       Date:  2017-08-12       Impact factor: 22.682

Review 3.  Surgical treatment of gastrointestinal stromal tumors of the stomach: current status and future perspective.

Authors:  Kheng Tian Lim
Journal:  Transl Gastroenterol Hepatol       Date:  2017-12-07

4.  Surgical Management of Adolescents and Young Adults With Gastrointestinal Stromal Tumors: A US Population-Based Analysis.

Authors:  Katherine E Fero; Taylor M Coe; Paul T Fanta; Chih-Min Tang; James D Murphy; Jason K Sicklick
Journal:  JAMA Surg       Date:  2017-05-01       Impact factor: 14.766

5.  Synchronous, Yet Genomically Distinct, GIST Offer New Insights Into Precise Targeting of Tumor Driver Mutations.

Authors:  Eleftherios A Makris; Ashwyn K Sharma; Erik N Bergstrom; Xiaojun Xu; Jorge de la Torre; Sudeep Banerjee; Vi Nguyen; Mojgan Hosseini; Adam Burgoyne; Olivier Harismendy; Ludmil B Alexandrov; Jason K Sicklick
Journal:  JCO Precis Oncol       Date:  2021-03-19

6.  The cut-off value of tumor size and appropriate timing of follow-up for management of minimal EUS-suspected gastric gastrointestinal stromal tumors.

Authors:  Zhidong Gao; Chao Wang; Qian Xue; Jingtong Wang; Zhanlong Shen; Kewei Jiang; Kai Shen; Bin Liang; Xiaodong Yang; Qiwei Xie; Shan Wang; Yingjiang Ye
Journal:  BMC Gastroenterol       Date:  2017-01-11       Impact factor: 3.067

7.  Prolonging Gastrointestinal-Stromal-Tumor-free life, an optimal suggestion of imatinib intervention ahead of operation.

Authors:  Lin-Hai Yan; Zhi-Ning Chen; Chun-Jun Li; Jia Chen; Yu-Zhou Qin; Jian-Si Chen; Wei-Zhong Tang
Journal:  J Cancer       Date:  2018-10-05       Impact factor: 4.207

8.  Distinctive features of gastrointestinal stromal tumors arising from the colon and rectum.

Authors:  Rebecca Zhu; Fangfang Liu; Gabriella Grisotti; Javier Pérez-Irizarry; Charles H Cha; Caroline H Johnson; Daniel J Boffa; Dale Han; Kimberly L Johung; Yawei Zhang; Sajid A Khan
Journal:  J Gastrointest Oncol       Date:  2018-04

9.  Which size is the best cutoff for primary small gastric gastrointestinal stromal tumor?

Authors:  Xingyu Feng; Zifeng Yang; Peng Zhang; Tao Chen; Haibo Qiu; Zhiwei Zhou; Guoxin Li; Kaixiong Tao; Hui Wang; Yong Li
Journal:  J Gastrointest Oncol       Date:  2020-04

Review 10.  Efficacy and safety of endoscopic resection in treatment of small gastric stromal tumors: A state-of-the-art review.

Authors:  Ze-Ming Chen; Min-Si Peng; Li-Sheng Wang; Zheng-Lei Xu
Journal:  World J Gastrointest Oncol       Date:  2021-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.